JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma | Acta Pharmacologica Sinica
JCI - Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma
Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
Frontiers | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Ibrutinib improves survival in young people with diffuse large B-cell lymphoma
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes | MedPage Today
Cancers | Free Full-Text | Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma | Annals of Hematology
Ibrutinib improves diffuse large B-cell lymphoma survival - NCI
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma | Nature Medicine
